|
|
Volumn 8, Issue 9, 2009, Pages 688-
|
|
Trial watch: BLYS-targeted antibody shows promise in Phase III SLE trial.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
B CELL ACTIVATING FACTOR;
BELIMUMAB;
MONOCLONAL ANTIBODY;
TNFSF13B PROTEIN, HUMAN;
AUTOIMMUNE DISEASE;
DRUG ANTAGONISM;
HUMAN;
IMMUNOLOGY;
NOTE;
PATHOPHYSIOLOGY;
PATIENT SELECTION;
PHASE 3 CLINICAL TRIAL;
SYSTEMIC LUPUS ERYTHEMATOSUS;
ANTIBODIES, MONOCLONAL;
AUTOIMMUNE DISEASES;
B-CELL ACTIVATING FACTOR;
CLINICAL TRIALS, PHASE III AS TOPIC;
HUMANS;
LUPUS ERYTHEMATOSUS, SYSTEMIC;
PATIENT SELECTION;
|
|
EID: 70249107193
PISSN: None
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2984 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|